Skip to search formSkip to main contentSkip to account menu

Centoxin

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
This paper examines the development and termination of nebacumab (Centoxin®), a human IgM monoclonal antibody (mAb) drug… 
2012
2012
SummaryMonoclonal antibodies have been shown to reduce morbidity and mortality in selected subsets of patients with Gram-negative… 
Review
2000
Review
2000
Meningococcal septic shock (MSS) has high mortality and morbidity rates. In addition to the traditional prompt antibiotics and… 
1998
1998
ABSTRACT This note describes the binding specificities of four lipid A monoclonal antibodies (MAbs) including Centoxin (HA-1A… 
1995
1995
Human IgM monoclonal antibody A6H4C5 was manufactured by Centocor (Malvern, PA) and used in clinical trials as HA-1A (Centoxin… 
1994
1994
  • Archives of internal medicine
  • 1994
  • Corpus ID: 23610306
BACKGROUND Antiendotoxin monoclonal antibodies are under investigation as adjunctive therapy for severe sepsis. One of these… 
1994
1994
ObjectiveThe in vivo neutralizing activities of an anti-lipopolysaccharide (LPS) antibody HA-1A (Centoxin [Centocor, Malvern, PA… 
1994
1994
The cytokines interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF alpha) have been… 
1993
1993
OBJECTIVE Evaluation of HA-1A treatment in patients with the sepsis syndrome. DESIGN Descriptive. SETTING Department of… 
1993
1993